| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 03/14/2002 | WO2001077147A3 New bromodomain protein |
| 03/14/2002 | WO2001076644A3 Lipid-based systems for targeting diagnostic agents |
| 03/14/2002 | WO2001076555A3 Lipid-based drug delivery systems for topical application |
| 03/14/2002 | WO2001072290A3 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 03/14/2002 | WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 03/14/2002 | WO2001070668B1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 03/14/2002 | WO2001068612A3 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 03/14/2002 | WO2001066543A3 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 03/14/2002 | WO2001066081A3 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 03/14/2002 | WO2001064046A3 Method for isolating sponge collagen and producing nanoparticulate collagen, and the use thereof |
| 03/14/2002 | WO2001062737A3 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 03/14/2002 | WO2001059129A3 Mammalian secreted group iii phospholipase a2 |
| 03/14/2002 | WO2001058852A3 (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils |
| 03/14/2002 | WO2001057085A3 G-protein coupled receptors |
| 03/14/2002 | WO2001055358A3 Phosphodiesterases |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001051512A3 Human and parasite orphan receptor proteins |
| 03/14/2002 | WO2001045715A3 Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain |
| 03/14/2002 | WO2001045684A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001045682A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001027267A3 Genes differentially expressed in tr1 cells and their use in the manufacture of immunoregulatory compositions |
| 03/14/2002 | WO2001023572A3 Polynucleotides and polypeptides encoded thereby |
| 03/14/2002 | WO2001002018A3 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 03/14/2002 | WO2000074662A3 Arthritis treatment |
| 03/14/2002 | WO2000053742A9 Polynucleotides and proteins encoded thereby |
| 03/14/2002 | US20020032306 Cyclopeptide derivatives |
| 03/14/2002 | US20020032226 Amorphous 5-(4-aminosulfonyl-3-fluorophenyl)-4-cyclohexyl-2-methyloxazole compound, free of crystals; improved water solubility; treatment of COX-2 mediated disorders. |
| 03/14/2002 | US20020032225 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020032213 Macrolides |
| 03/14/2002 | US20020032212 A tricyclic compound (with oxy and nitrogen atoms in the ring); perticularly useful for treating or preventing psoriasis and other skin diseases |
| 03/14/2002 | US20020032210 Chloride channel blockers; useful in the treatment of sickle cell anaemia, brain edema following iscaemia or tumors, diarrhea, hypertension, bone metabolic disorders, osteoclast associated disoders; substituted biphenyl containing nitrogen |
| 03/14/2002 | US20020032204 Reacting a substituted indol-2-one compound with an acyclic or cyclic amine free of piperidine-1-yl or morpholine-4-yl to form protein kinase inhibitor |
| 03/14/2002 | US20020032202 Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia |
| 03/14/2002 | US20020032196 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032194 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032191 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors |
| 03/14/2002 | US20020032169 Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue |
| 03/14/2002 | US20020031793 Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices |
| 03/14/2002 | US20020031544 Antiinflammatory agents |
| 03/14/2002 | US20020031512 Inhibiting immunological activation of keratinocytes by administering molecule that binds to CD40 but does not activate CD40-expressing keratinocytes |
| 03/14/2002 | US20020031507 Treatment of inflammatory processes of the intestine, hypercholesterolaemia and infections with Helicobacter pylori; anticarcinogenic agent |
| 03/14/2002 | US20020031496 Therapy for cellular accumulation in chronic inflammatory diseases |
| 03/14/2002 | US20020031490 Method for preparing resinates |
| 03/14/2002 | DE10128266A1 Verfahren zur Herstellung eines Extrakts mit starker Antiinflammations-Antiblutplättchenaggregations- und Antifungi-Aktivität aus Zingiber officinale und pharmazeutische Zusammensetzungen, die diesen Extrakt enthalten A process for preparing an extract with a strong Antiinflammations-Antiblutplättchenaggregations- and antifungal activity of Zingiber officinale and pharmaceutical compositions containing this extract |
| 03/14/2002 | DE10041402A1 Neue Verbindungen, die Faktor Xa-Aktivität inhibieren Novel compounds which inhibit factor Xa activity |
| 03/14/2002 | DE10041217A1 Verwendung von Dihydroboswelliasäuren oder hydrierten Extrakten aus Boswellia zur prophylaktischen und/oder therapeutischen Behandlung von unerwünschten körperlichen oder seelischen Zuständen Use of Dihydroboswelliasäuren or hydrogenated extracts of Boswellia for prophylactic and / or therapeutic treatment of unwanted physical or mental conditions |
| 03/14/2002 | DE10040771A1 Neue, 224Ra enthaltende, radiotherapeutisch wirksame Formulierungen und Verfahren zu ihrer Herstellung New, high 224Ra, radio therapeutically effective formulations and methods for their preparation |
| 03/14/2002 | DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments |
| 03/14/2002 | CA2422204A1 Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421842A1 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | CA2421274A1 Method for down-regulating ige |
| 03/14/2002 | CA2421271A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | CA2421251A1 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 03/14/2002 | CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | CA2421195A1 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | CA2421191A1 Methods and compositions for in vitro targeting |
| 03/14/2002 | CA2421041A1 Caveolin peptides and their use as therapeutics |
| 03/14/2002 | CA2419601A1 The treatment of inflammatory disorders |
| 03/14/2002 | CA2417177A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/14/2002 | CA2412279A1 "pseudo"-native chemical ligation |
| 03/14/2002 | CA2412278A1 Polymer-modified synthetic proteins |
| 03/14/2002 | CA2412277A1 Synthetic erythropoiesis stimulating proteins |
| 03/13/2002 | EP1186603A2 Processes for preparing endothelin antagonists |
| 03/13/2002 | EP1185700A1 49 human secreted proteins |
| 03/13/2002 | EP1185696A1 Antisense oligonucleotide modulation of human protein kinase c-delta expression |
| 03/13/2002 | EP1185694A1 49 human secreted proteins |
| 03/13/2002 | EP1185652A2 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto |
| 03/13/2002 | EP1185555A2 Compositions isolated from skin cells and methods for their use |
| 03/13/2002 | EP1185554A1 Peptide having for fibrinogen fragment e activity, analogs, antibodies and uses thereof |
| 03/13/2002 | EP1185547A2 Gene expression modulated in gastrointestinal inflammation |
| 03/13/2002 | EP1185543A1 50 human secreted proteins |
| 03/13/2002 | EP1185542A2 Purine derivatives |
| 03/13/2002 | EP1185532A1 Peroxynitrite decomposition catalysts and methods of use thereof |
| 03/13/2002 | EP1185528A1 Inhibitors of il-12 production |
| 03/13/2002 | EP1185524A2 3-heteroarylalkyl substituted gaba analogs |
| 03/13/2002 | EP1185522A1 Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions containing them |
| 03/13/2002 | EP1185316A1 Devices and compounds for treating arterial restenosis |
| 03/13/2002 | EP1185304A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells |
| 03/13/2002 | EP1185302A2 Specifically targeted catalytic antagonists and uses thereof |
| 03/13/2002 | EP1185296A2 Prevention and treatment of amyloidogenic disease |
| 03/13/2002 | EP1185291A2 Therapeutic agent comprising a botulinum neurotoxin |
| 03/13/2002 | EP1185286A1 Mu o-conopeptides and their use as local anesthetics |
| 03/13/2002 | EP1185285A1 49 human secreted proteins |
| 03/13/2002 | EP1185284A1 47 human secreted proteins |
| 03/13/2002 | EP1185272A2 Novel use of 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts |
| 03/13/2002 | EP1185253A2 Oral administration form for administering a fixed tramadol and diclofenac combination |
| 03/13/2002 | EP1185247A1 Anti-inflammatory bioactive glass particulates |
| 03/13/2002 | EP1185246A1 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water |
| 03/13/2002 | EP1185241A2 Compositions containing avenanthramides from oat extract |
| 03/13/2002 | EP0983249B1 Processes and intermediates for preparing substituted indazole derivatives |
| 03/13/2002 | EP0977749B1 Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing same |
| 03/13/2002 | CN1340103A Complex-forming proteins |
| 03/13/2002 | CN1340102A Polypeptide variants with raised heparin-binding capacity |
| 03/13/2002 | CN1340058A Compounds which inhibit leukocyte adhesion mediated by VLA-4 |